{"id":457405,"date":"2021-03-15T08:03:16","date_gmt":"2021-03-15T12:03:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457405"},"modified":"2021-03-15T08:03:16","modified_gmt":"2021-03-15T12:03:16","slug":"reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/","title":{"rendered":"Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, March  15, 2021  (GLOBE NEWSWIRE) &#8212; Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the appointment of Eric Dube, Ph.D. to the company\u2019s Board of Directors.<\/p>\n<p align=\"justify\">\u201cWe are very pleased to announce the addition of Eric Dube to the Reneo Board,\u201d said Gregory J. Flesher, President and Chief Executive Officer of Reneo. \u201cEric is an accomplished pharmaceutical industry executive and a leader in the rare disease field. We look forward to his guidance and insights as we work to advance REN001 and lead Reneo to its next phase of development.\u201d<\/p>\n<p align=\"justify\">\u201cI am very pleased to be joining the strong team at Reneo,\u201d said Dr. Dube. \u201cI look forward to working alongside Greg and Executive Chairman, Mike Grey, as well as the rest of the Board and management team to advance Reneo\u2019s promising pipeline that has the potential to address significant unmet needs for people living with rare genetic mitochondrial diseases.\u201d<\/p>\n<p align=\"justify\">Dr. Dube is the President, Chief Executive Officer and a Director of Travere Therapeutics, a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare disease. Prior to joining Travere Therapeutics, Dr. Dube was President and head of North America at ViiV Healthcare, where he led the commercialization of pipeline assets and oversaw the governance of all pricing, strategy, policy, and investment decisions for the company\u2019s North America business. Before joining ViiV, for more than 18 years he worked in roles of increasing leadership at GlaxoSmithKline plc, spanning critical areas, including sales, marketing, market access, medical affairs, compliance, supply chain, and alliance management. During Dr. Dube\u2019s tenure at GSK, he also led the US Oncology and Global Respiratory businesses. Dr. Dube currently serves on the Board of Trustees for AIDS United and the Board of Directors for the Biotechnology Innovation Organization (BIO) and Biocom California. Dr. Dube has previously been named a Fortune magazine \u201c40 Under 40: Ones to Watch\u201d and one of the \u201cEmerging Pharma Leaders\u201d by Pharmaceutical Executive. He has also been named by the Financial Times as one of the \u201cOUTstanding 100 LGBT+ Executives.\u201d<\/p>\n<p align=\"justify\">Dr. Dube graduated from Santa Clara University with a B.S. in biopsychology and earned an M.A. and Ph.D. in psychology from Cornell University.<\/p>\n<p align=\"justify\">\n        <strong>About<\/strong><br \/>\n        <strong>\u00a0REN001<\/strong>\n      <\/p>\n<p align=\"justify\">REN001 is an oral selective peroxisome proliferator-activated receptor delta (PPAR\u03b4) agonist currently in clinical development for three rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease). For more information on REN001 clinical trials, please see <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Lf9G7g9mkDWzveCeFwuMiFfvIH87xdAv0NepYV50PqaD1WHwMXMBl0LM5kJEgQuepAiAaPjDiz3CLWz-WCqfor_GzMHZ0MBQ3xg-9K9wMsZtj6sOSE73ausMXexYNXQC-APlEFgOncIuS1SlzxNk8sCUWh7m2CVDfOki9CthMRBOYuCGwYCnxxAe_6NZT30u4tKeHNAc17Ze61mFfvapJjtiUnhcxn__wP5OUvU5C4o=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">clinicaltrials.gov<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About<\/strong><br \/>\n        <strong>\u00a0Reneo Pharmaceuticals<\/strong>\n      <\/p>\n<p align=\"justify\">Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.<\/p>\n<p align=\"justify\">For\u00a0more information,\u00a0please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oGQHfj9plGtNq_ck0aPplU1Yut9FMjHsNOZlrlcb-S8UuwSwe9edMWKCgSKmYu3OEs9ojHj_yL5t90n4y31SVQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">reneopharma.com<\/a><\/p>\n<p>Contacts:<\/p>\n<p>Joyce\u00a0Allaire<br \/><em>Managing<\/em><em>\u00a0Director<\/em><br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TI2IV5S5mn9QK9hdFZu5OMvpwszQE856lk75n106VnburwqbZE0bpw-BXv20FUyfhuQsppomjoPrXzJ8oI3uPwMwtqojCXQGlBL4gwhKzWkNhVx6USmkC2lkGQPYI7Pu\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jallaire@lifesciadvisors.com<\/a><\/p>\n<p>Michael\u00a0Cruse<br \/><em>SVP<\/em><em>\u00a0Corporate Operations<\/em><br \/>Reneo Pharmaceuticals, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wUNo09s_tn7CqwnBFzuwdoa7cnxCK_fyzNcSPE6vT5gaj2xOHmsr6-MjAsVCETqyoQwwN1Nn_Mqe_zSCsM26LD_rhKV76yCvJ1MPDDH3mo4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mcruse@reneopharma.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTQ3MSM0MDYyMzYxIzUwMDA3ODUxOA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/259c77e9-bdaa-46ed-a1d6-12ecab30074c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) &#8212; Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the appointment of Eric Dube, Ph.D. to the company\u2019s Board of Directors. \u201cWe are very pleased to announce the addition of Eric Dube to the Reneo Board,\u201d said Gregory J. Flesher, President and Chief Executive Officer of Reneo. \u201cEric is an accomplished pharmaceutical industry executive and a leader in the rare disease field. We look forward to his guidance and insights as we work to advance REN001 and lead Reneo to its next phase of development.\u201d \u201cI am very pleased to be joining the strong team at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457405","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) &#8212; Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the appointment of Eric Dube, Ph.D. to the company\u2019s Board of Directors. \u201cWe are very pleased to announce the addition of Eric Dube to the Reneo Board,\u201d said Gregory J. Flesher, President and Chief Executive Officer of Reneo. \u201cEric is an accomplished pharmaceutical industry executive and a leader in the rare disease field. We look forward to his guidance and insights as we work to advance REN001 and lead Reneo to its next phase of development.\u201d \u201cI am very pleased to be joining the strong team at &hellip; Continue reading &quot;Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T12:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTQ3MSM0MDYyMzYxIzUwMDA3ODUxOA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors\",\"datePublished\":\"2021-03-15T12:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/\"},\"wordCount\":580,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTQ3MSM0MDYyMzYxIzUwMDA3ODUxOA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/\",\"name\":\"Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTQ3MSM0MDYyMzYxIzUwMDA3ODUxOA==\",\"datePublished\":\"2021-03-15T12:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTQ3MSM0MDYyMzYxIzUwMDA3ODUxOA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTQ3MSM0MDYyMzYxIzUwMDA3ODUxOA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors - Market Newsdesk","og_description":"SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) &#8212; Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the appointment of Eric Dube, Ph.D. to the company\u2019s Board of Directors. \u201cWe are very pleased to announce the addition of Eric Dube to the Reneo Board,\u201d said Gregory J. Flesher, President and Chief Executive Officer of Reneo. \u201cEric is an accomplished pharmaceutical industry executive and a leader in the rare disease field. We look forward to his guidance and insights as we work to advance REN001 and lead Reneo to its next phase of development.\u201d \u201cI am very pleased to be joining the strong team at &hellip; Continue reading \"Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T12:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTQ3MSM0MDYyMzYxIzUwMDA3ODUxOA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors","datePublished":"2021-03-15T12:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/"},"wordCount":580,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTQ3MSM0MDYyMzYxIzUwMDA3ODUxOA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/","name":"Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTQ3MSM0MDYyMzYxIzUwMDA3ODUxOA==","datePublished":"2021-03-15T12:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTQ3MSM0MDYyMzYxIzUwMDA3ODUxOA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTQ3MSM0MDYyMzYxIzUwMDA3ODUxOA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reneo-pharmaceuticals-appoints-eric-dube-ph-d-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457405"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457405\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}